INTERNATIONAL SPECIALTY PRODUCTS INC /NEW/ Form 10-Q May 16, 2001

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED APRIL 1, 2001

OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 000-29764

INTERNATIONAL SPECIALTY PRODUCTS INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE (State of Incorporation)

51-0376469 (I. R. S. Employer Identification No.)

300 DELAWARE AVENUE, SUITE 303, WILMINGTON, DELAWARE19801(Address of principal executive offices)(Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (302) 427-5715

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /X/ No / /

As of May 11, 2001, 66,130,589 shares of International Specialty Products Inc. common stock (par value \$.01 per share) were outstanding.

47201.0001

PART I - FINANCIAL INFORMATION ITEM 1 - FINANCIAL STATEMENTS

INTERNATIONAL SPECIALTY PRODUCTS INC.

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	QUARTER ENDED		
		APRIL 1, 2001	
Net sales		\$ 203,197	
Costs and expenses: Cost of products sold Selling, general and administrative Goodwill amortization	129,434 38,862 4,048	133,263 39,977 4,048	
Total costs and expenses		177,288	
Operating income Interest expense Gain on contract settlement Other income, net	25,597 (19,722) 3,450	25,909 (19,051) - 28,499	
Income before income taxes Income taxes	11,788	35,357	
Income before cumulative effect of accounting change Cumulative effect of change in accounting	7,672	22 , 955	
principle, net of income tax benefit of \$216	_	(440)	
Net income	\$7,672		

INTERNATIONAL SPECIALTY PRODUCTS INC.

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - (CONTINUED) (THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	QUARTER ENDED			
		RIL 2, 2000		PRIL 1, 2001
Earnings per common share:				
Basic:				
Income before cumulative effect of				
accounting change	Ş	.11	Ş	.35
Cumulative effect of accounting change		-		(.01)
Net income	\$.11	\$.34
	====		====	
Diluted:				
Income before cumulative effect of				
accounting change	\$.11	\$.35
Cumulative effect of accounting change		-		(.01)

Net income	\$.11	\$.34
	====		====	
Weighted average number of common and common equivalent shares outstanding:				
Basic	6	8,849		66,328 =====
Diluted	6	8,857		66 , 373
	====:			

The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.

2

INTERNATIONAL SPECIALTY PRODUCTS INC.

CONSOLIDATED BALANCE SHEETS

	DECEMBER 31, 2000	APRIL 1, 2001 (UNAUDITED)
	(THOU	ISANDS)
ASSETS		
Current Assets:	¢ 10 101	¢ 12.000
Cash and cash equivalents		\$ 13,909
Investments in trading securities Investments in available-for-sale securities	303,103	312,874
Other short-term investments	222,327	190,440
	19,129	20,039
Accounts receivable, trade, net	89,173	93,236 20,666
Accounts receivable, other	19,596 11,624	17,355
Receivable from related parties, net	150,948	160,234
Other current assets	36,928	39,277
Other current assets		
Total Current Assets	871,009	868,030
Property, plant and equipment, net	562,973	557,454
Goodwill, net	494,386	490,338
Other assets	31,916	29,075
Total Assets	\$1,960,284	\$1,944,897
LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities:		
Short-term debt	\$ 143,682	\$ 135 , 571
Current maturities of long-term debt	224,419	463,264
Accounts payable	58,238	55,668
Accrued liabilities	91,309	88,288
Income taxes	13,610	14,571
Total Current Liabilities	531,258	757,362
Long-term debt less current maturities	524,780	324,885

Deferred income taxes	151,181	•
Other liabilities		
Stockholders' Equity:		
Preferred stock, \$.01 par value per share; 20,000,000 shares authorized:		
no shares issued	-	-
Common stock, \$.01 par value per share;		
300,000,000 shares authorized: 69,546,456		
shares issued	695	695
Additional paid-in capital	485,629	485,771
Unearned compensation - restricted stock awards	(1,287)	(1, 179)
Treasury stock, at cost - 3,135,192 and		
3,265,282 shares, respectively	(19 631)	(20,654)
Retained earnings	· · · ·	236,443
-	•	
Accumulated other comprehensive income(loss)	12,001	(36,786)
Total Stockholders' Equity	691 , 335	664,290
Total Liabilities and Stockholders' Equity	\$1,960,284	\$1,944,897

The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.

3

INTERNATIONAL SPECIALTY PRODUCTS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	QUARTER ENDED	
	APRIL 2, 2000	APRIL 1, 2001
		USANDS)
Cash and cash equivalents, beginning of period	\$ 23,309	
Cash provided by operating activities: Net income Adjustments to reconcile net income to net cash provided by operating activities:		22 , 515
Cumulative effect of change in accounting principle Depreciation Goodwill amortization Deferred income taxes	- 12,432 4,048 (1,242)	12,959 4,048
Unrealized gains on trading securities and other short-term investments Increase in working capital items Purchases of trading securities Proceeds from sales of trading securities Increase in net receivable from related parties Change in cumulative translation adjustment	(12,124) (18,906) 34,564 (2,404)	(20,612) (23,869) (143,546) 153,241 (5,731) (5,093)
Other, net		5,585

Net cash provided by operating activities	5,796	
Cash provided by (used in) investing activities:		
Capital expenditures	(11,284)	(9,872)
Purchases of available-for-sale securities	(94,678)	(45,754)
Proceeds from sales of available-for-sale securities	64,398	12,291
Proceeds from sales of other short-term investments	-	236
Net cash used in investing activities	(41,564)	
Cash provided by (used in) financing activities:		
Proceeds (repayments) from sale of accounts receivable.	(5,675)	1,475
Increase (decrease) in short-term debt	41,566	(8,111)
Increase in borrowings under revolving credit facility.	21,100	67 , 100
Repayments of long-term debt	(110)	(28,180)
Repurchases of common stock	-	(1,219)
Other, net	530	124
Net cash provided by financing activities	57,411	31,189
Net change in cash and cash equivalents	21,643	(4,272)
Cash and cash equivalents, end of period	\$ 44,952	

4

INTERNATIONAL SPECIALTY PRODUCTS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) -- (CONTINUED)

	QUARTER ENDED	
	APRIL 2, 2000	APRIL 1, 2001
	(THOU	USANDS)
Supplemental Cash Flow Information: Cash paid during the period for:		
Interest (net of amount capitalized)		\$ 16,228
Income taxes	4,722	3,125

The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.

5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements for International Specialty Products Inc. (the "Company") reflect, in the opinion of management, all adjustments necessary to present fairly the financial position of the Company at April 1, 2001, and the results of operations and cash flows for the periods ended April 2, 2000 and April 1, 2001. All adjustments are of a normal recurring nature. These financial statements should be read in conjunction with the annual financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000 (the "Form 10-K").

NOTE 1. CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE

In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 133, "Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133 establishes accounting and reporting standards requiring that every derivative instrument be recorded in the balance sheet as either an asset or liability measured at its fair value. SFAS No. 133 requires that changes in a derivative's fair value be recognized currently in earnings unless specific hedge accounting criteria are met. Special accounting for qualifying hedges allows a derivative's gains and losses to offset related results on the hedged item in the income statement.

The Company adopted SFAS No. 133 as of January 1, 2001. Accounting for interest rate swaps and foreign exchange forward contracts held by the Company is affected by implementation of this standard. The earnings impact of the transition adjustments related to the initial adoption of the standard was an after-tax loss of \$0.4 million, which was recorded in the first quarter of 2001 as the cumulative effect of a change in accounting principle.

NOTE 2. HEDGING AND DERIVATIVES

The Company maintains a \$400 million bank revolving credit facility, with the majority of outstanding borrowings against this facility indexed to LIBOR. The Company has designated interest rate swaps, with a notional amount of \$100 million, as a hedge of its exposure to changes in LIBOR. The interest rate swaps are structured to receive interest based on LIBOR and pay interest on a fixed rate basis. A cash flow hedging relationship has been established whereby the interest rate swaps hedge the risk of changes in LIBOR related to forecasted borrowings against the bank credit facility. The interest rate swaps hedge forecasted exposure to changes in LIBOR through July 2002.

During the first quarter of 2001, a \$0.1 million charge related to the reduction in the fair market value of the interest rate swaps was reclassified and charged against interest expense. As of April 1, 2001, the reclassification charge to earnings related to interest accruals over the next twelve months is estimated to be \$1.7 million.

Derivatives held by the Company not designated as hedging instruments include total return equity swaps and forward foreign exchange instruments. The total return equity swaps are held for investment income purposes. Foreign

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

exchange forward contracts are held to offset exposure to changes in exchange rates affecting intercompany loans.

NOTE 3. COMPREHENSIVE INCOME

NOTE 5. COMPREMENSIVE INCOME		Quarter Ended		
	April 2, 2000	April 1, 2001		
		sands)		
Net income		\$ 22,515		
Other comprehensive income (loss), net of tax: Change in unrealized gains (losses) on available-for-sale securities: Unrealized holding gains (losses) arising during the period, net of income tax (provision) benefit of \$(20,419) and \$22,867 Less: reclassification adjustment for gains (losses) included in net income,		(42,307)		
<pre>net of income tax (provision) benefit of \$1,436 and \$(283)</pre>	(3,000)	524		
Total change for the period	43,238			
Change in unrealized losses on derivative hedging instruments - cash flow hedges: Net derivative losses, net of tax effect of \$495 Less: reclassification adjustment for losses included in net income, net of tax effect	_	(914)		
of \$28		(51)		
Total change for the period	_ (6,282)	(863)		
Total other comprehensive income (loss)	36,956			
Comprehensive income (loss)		\$ (26,272)		

Changes in the components of "Accumulated other comprehensive income (loss)" for the quarter ended April 1, 2001 are as follows:

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Unrealized Unrealized Cumulative

	On foi	ins (Losses) Available- c-Sale curities	Hedgi	vative	Cu: Tra	reign rrency anslation justment	Ot Cc	ccumulated her omprehensive ncome (Loss)
				(Thous	and	5)		
Balance, December 31, 2000 Change for the period	\$	34,020 (42,831)	\$	- (863)	\$	(22,019) (5,093)	\$	12,001 (48,787)
Balance, April 1, 2001	\$ ====	(8,811)	\$ ====	(863)	\$	(27,112)	\$	(36,786)

NOTE 4. BUSINESS SEGMENT INFORMATION

NOIE 4. BUSINESS SEGMENI INFORMATION	Quarter Ended		
	April 2, 2000	April 1,	
	(Thous	sands)	
Net sales: Personal Care Pharmaceutical, Food and Beverage Performance Chemicals, Fine Chemicals and		\$ 56,243 57,399	
Industrial	70,930	71,123	
Total Specialty Chemicals Mineral Products (1)	179,380 18,561	184,765	
Net sales		\$ 203 , 197	
Operating income(2):			
Personal Care Pharmaceutical, Food and Beverage Performance Chemicals, Fine Chemicals and	\$ 8,591 12,685	\$ 12,171 12,839	
Industrial		(64)	
Total Specialty Chemicals Mineral Products	22,991 2,629	24,946	
Total segment operating income Unallocated corporate office	25,620 (23)	25,520	
Total operating income Interest expense and other, net	(13,809)	25,909	
Income before income taxes		\$ 35,357	

- Includes sales to Building Materials Corporation of America, an affiliate, and its subsidiaries, of \$16.3 and \$15.2 million for the first quarter of 2000 and 2001, respectively.
- (2) Operating income for the first quarter of 2000 for the three Specialty Chemicals business segments have been reclassified to conform to the 2001 presentation, based on a reallocation of certain manufacturing costs.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 5. INVENTORIES

Inventories comprise the following:

	December 31, 2000	April 1, 2001`
	(Thous	ands)
Finished goods	\$ 93,356	\$ 97 , 237
Work-in-process	29,022	33,845
Raw materials and supplies	28,570	29,152
Inventories	\$150,948	\$ 160,234
		========

At December 31, 2000 and April 1, 2001, \$38.7 and \$49.0 million, respectively, of domestic inventories were valued using the LIFO method. If the FIFO inventory method had been used for these inventories, they would have been \$0.1 million lower at December 31, 2000 and \$5.7 million higher at April 1, 2001. The change in the LIFO reserve in the first quarter of 2001 was attributable to a revaluation of FIFO standard costs effective January 1, 2001.

NOTE 6. LONG-TERM DEBT

In January 2001, the Company repaid the \$28.1 million mortgage on its headquarters property. Current maturities of long-term debt at April 1, 2001 include \$199.9 million of 9 3/4% Senior Notes due February 2002 and \$263.1 million of borrowings outstanding under the Company's bank credit agreement based on the expiration of the bank credit agreement in July 2001.

NOTE 7. RESTRUCTURING RESERVES

In December 2000, the Company shut down its Seadrift, Texas butanediol manufacturing facility and shut down production of butanediol at its Texas City, Texas manufacturing facility in the first quarter of 2001. Accordingly, the Company recorded a one-time restructuring charge against operating income in 2000 of \$2.5 million, including an accrual of \$2.1 million for cash costs to be incurred in 2001 for severance costs and for decommissioning and remediation costs. In the first quarter of 2001, \$0.6 million of costs were charged against this reserve, primarily for severance costs, leaving a reserve balance of \$1.5 million as of the end of the first quarter of 2001.

In connection with the relocation of certain of the Company's production lines for Personal Care products to the Company's Freetown, Massachusetts facility, the Company shut down substantially all of its manufacturing operation in Belleville, New Jersey in the first quarter of 2001. Accordingly, the Company recorded a restructuring charge against operating income in 2000 of \$11.9 million, which included a \$10.4 million write-off of production assets. The total charge included an accrual of \$1.5 million for cash costs to be incurred in 2001, mainly for severance and for other shutdown-related costs. In the first quarter of 2001, \$0.3 million of costs were charged against this reserve,

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

principally for severance costs, leaving a reserve balance of \$1.2 million as of the end of the first quarter of 2001.

NOTE 8. CONTINGENCIES

Environmental Litigation

The Company, together with other companies, is a party to a variety of proceedings and lawsuits involving environmental matters ("Environmental Claims"), in which recovery is sought for the cost of cleanup of contaminated sites, a number of which Environmental Claims are in the early stages or have been dormant for protracted periods.

In the opinion of the Company's management, the resolution of the Environmental Claims should not be material to the business, liquidity, results of operations, cash flows or financial position of the Company. However, adverse decisions or events, particularly as to the liability and the financial responsibility of the Company's insurers and of the other parties involved at each site and their insurers, could cause the Company to increase its estimate of its liability in respect of such matters. It is not currently possible to estimate the amount or range of any additional liability.

For further information regarding environmental matters, reference is made to Note 19 to Consolidated Financial Statements contained in the Form 10-K.

Tax Claim Against G-I Holdings Inc.

The Company was a party to tax sharing agreements with members of the consolidated group (the "G-I Holdings Group") that included GAF Corporation and G-I Holdings Inc. ("G-I Holdings") in 1990 and, accordingly, would be severally liable for any tax liability of the G-I Holdings Group in respect of such year. Effective as of January 1, 1997, neither the Company nor any of its subsidiaries are members of the G-I Holdings Group.

On September 15, 1997, G-I Holdings received a notice from the Internal Revenue Service (the "IRS") of a deficiency in the amount of \$84.4 million (after taking into account the use of net operating losses and foreign tax credits otherwise available for use in later years) in connection with the formation in 1990 of Rhone-Poulenc Surfactants and Specialties, L.P. (the "surfactants partnership"), a partnership in which a predecessor of G-I Holdings held an interest. The claim of the IRS for interest and penalties, after taking into account the effect on the use of net operating losses and foreign tax credits, could result in G-I Holdings incurring liabilities significantly in excess of the deferred tax liability of \$131.4 million that it recorded in 1990 in connection with this matter. G-I Holdings has advised the Company that it believes that it will prevail in this matter, although there can be no assurance

10

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

in this regard. The Company believes that the ultimate disposition of this matter will not have a material adverse effect on its business, financial position or results of operations. The Company, together with G-I Holdings and several current and former subsidiaries of G-I Holdings, would be severally liable for such taxes, interest and penalties should G-I Holdings be unable to

satisfy such liability. In January 2001, G-I Holdings filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code due to its asbestos-related bodily injury claims relating to the inhalation of asbestos fiber. For additional information relating to G-I Holdings, reference is made to Notes 8, 16 and 19 to Consolidated Financial Statements contained in the Form 10-K.

11

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations - First Quarter 2001 Compared With First Quarter 2000

The Company recorded first quarter 2001 net income of \$22.5 million (\$.34 diluted earnings per share) compared with \$7.7 million (\$.11 diluted earnings per share) in the first quarter of 2000. The results for the first quarter of 2001 include an after-tax charge of \$0.4 million (\$.01 diluted earnings per share), representing the cumulative effect of adopting Statement of Financial Accounting Standards No. 133, "Accounting for Derivative Instruments and Hedging Activities." Excluding the effect of such charge and a one-time gain of \$3.5 million in the first quarter of 2000 from a contract settlement, net income for the first quarter of 2001 was \$23.0 million (\$.35 diluted earnings per share) versus \$5.4 million (\$.08 diluted earnings per share) in the same period last year. On a comparable basis, the improved results were attributable to higher investment income, lower interest expense and higher operating income.

Net sales for the first quarter of 2001 were \$203.2 million compared with \$197.9 million for the same period in 2000. The increase in sales resulted primarily from higher unit volumes in the Personal Care, Pharmaceutical and Performance Chemicals businesses and improved pricing in the Industrial business, partially offset by lower unit volumes in the Industrial and Alginates businesses and by the adverse effect of the stronger U.S. dollar in Europe.

Operating income for the first quarter of 2001 was \$25.9 million compared with \$25.6 million for the first quarter of 2000. The increase was primarily attributable to an improvement in operating income in the Personal Care business segment as a result of higher unit volumes and an improved product mix, and, to a lesser extent, higher unit volumes in the Pharmaceutical business, partially offset by lower volumes in the Alginates business, higher energy costs in the Mineral Products business segment, unfavorable results in the Fine Chemicals business and by the adverse effect of the stronger U.S. dollar in Europe.

Interest expense for the first quarter of 2001 was \$19.1 million versus \$19.7 million for the same period last year. The decrease was due mainly to lower average interest rates and, to a lesser extent, lower average borrowings. Other income, net, for the quarter was \$28.5 million compared with \$2.5 million

in last year's first quarter, with the improvement due to higher investment income.

Business Segment Review

A discussion of operating results for each of the Company's business segments follows. The Company operates its Specialty Chemicals business through three reportable business segments, in addition to the Mineral Products segment.

12

Personal Care

Sales in the first quarter of 2001 were \$56.2 million compared with \$48.6 million for the same period last year, while operating income for the first quarter of 2001 increased to \$12.2 million from \$8.6 million in last year's quarter. The 16% increase in sales and 42% improvement in operating income resulted from higher unit volumes and an improved product mix, primarily in the North American and European hair care markets, partially offset by the adverse effect of the stronger U.S. dollar in Europe.

Pharmaceutical, Food and Beverage ("PFB")

Sales for the PFB segment were \$57.4 million for the first quarter of 2001 compared with \$59.8 million for the first quarter of 2000, while operating income increased to \$12.8 million versus \$12.7 million last year. Sales for the Pharmaceutical and Beverage business increased by 4.5% in the first quarter of 2001, primarily reflecting higher Pharmaceutical unit volumes in the antiseptics market in Europe and Asia-Pacific and in the excipients market in Asia-Pacific. Sales for the Alginates business decreased by 24% due to lower unit volumes in non-food paper and pharmaceutical accounts.

Operating income for the Pharmaceutical and Beverage business increased 19% in the first quarter of 2001 compared with the same period in 2000, while the operating margin improved from 24% in the first quarter of 2000 to 27% in this year's quarter. The improvement reflected the higher unit volumes and lower administrative expenses. Operating income for the Alginates business decreased by 61% in the first quarter of 2001 due to an unfavorable product mix, the lower unit volumes and, to a lesser extent, higher distribution expenses.

Performance Chemicals, Fine Chemicals and Industrial

Sales in the first quarter of 2001 were \$71.1 million compared with \$70.9 million in the first quarter of 2000. The higher sales were primarily attributable to an 11% sales increase for the Performance Chemicals business, reflecting volume increases in Europe, Asia-Pacific and North America, and improved pricing in the Industrial business, partially offset by lower Industrial unit volumes and the unfavorable impact (\$2.2 million) of the stronger U.S. dollar in Europe.

Operating results for the Performance Chemicals, Fine Chemicals and Industrial segment reflected a loss of \$0.1 million for the first quarter of 2001 versus operating income of \$1.7 million for the same period last year. Operating income for the Performance Chemicals business remained level with the first quarter of 2000 due to lower gross margins, as the effect of unit volume increases were offset by an unfavorable product mix in Europe and by the impact of the stronger U.S. dollar. The operating loss for the Industrial business increased by \$1.0 million over last year's quarter as a result of unfavorable manufacturing costs and lower unit volumes and, to a lesser extent, the unfavorable impact of the stronger U.S. dollar, partially offset by improved

pricing. The Fine Chemicals business experienced a slight operating loss in the first quarter of 2001 as a result of lower unit volumes, an unfavorable product mix and increased operating expenses.

Mineral Products

Sales for the Mineral Products segment for the first quarter of 2001 were \$18.4 million compared with \$18.6 million for the first quarter of 2000. The lower sales were attributable to \$1.1 million lower sales to Building Materials Corporation of America, an affiliate, partially offset by \$0.9 million higher trade sales. Operating income for the first quarter of 2001 was \$0.6 million compared with \$2.6 million for the first quarter of 2000, reflecting lower gross margins due to higher energy costs and unfavorable pricing, and also higher operating expenses due mainly to an increased provision for doubtful accounts.

Liquidity and Financial Condition

During the first quarter of 2001, the Company's net cash outflow before financing activities was \$35.5 million, including \$7.6 million of cash generated from operations, the reinvestment of \$9.9 million for capital programs and the use of \$33.2 million of cash for net purchases of available-for-sale securities and other short-term investments.

Cash generated from operations in the first quarter of 2001 reflected a \$10.9 million net cash outflow related to investments in trading securities. Excluding this cash outflow, cash provided from operations totaled \$18.6 million. Cash invested in additional working capital totaled \$23.9 million during the first quarter of 2001, mainly reflecting a \$9.3 million increase in inventories, a \$6.6 million increase in receivables due to higher sales in the first quarter of 2001 compared with the fourth quarter of 2000, and a \$6.6 million net decrease in payables and accrued liabilities.

Net cash provided by financing activities during the first quarter of 2001 totaled \$31.2 million, reflecting a \$67.1 million increase in borrowings under the Company's bank revolving credit facility, partially offset by repayments of long-term debt totaling \$28.2 million and an \$8.1 million decrease in short-term borrowings. In addition, financing activities included a \$1.2 million cash outlay for repurchases of 161,500 shares of the Company's common stock pursuant to the Company's repurchase program. At April 1, 2001, 225,362 shares of common stock remained to be purchased under the Company's repurchase program.

As a result of the foregoing factors, cash and cash equivalents decreased by \$4.3 million during the first quarter of 2001 to \$13.9 million, excluding \$523.4 million of trading and available-for-sale securities and other short-term investments.

14

In December 2000, the Company shut down its Seadrift, Texas butanediol manufacturing facility and shut down production of butanediol at its Texas City, Texas manufacturing facility in the first quarter of 2001. Accordingly, the Company recorded a one-time restructuring charge against operating income in 2000 of \$2.5 million, including an accrual of \$2.1 million for cash costs to be incurred in 2001 for severance costs and for decommissioning and remediation

costs. In the first quarter of 2001, \$0.6 million of costs were charged against this reserve, primarily for severance costs, leaving a reserve balance of \$1.5 million as of the end of the first quarter of 2001.

In connection with the relocation of certain of the Company's production lines for Personal Care products to the Company's Freetown, Massachusetts facility, the Company shut down substantially all of its manufacturing operation in Belleville, New Jersey in the first quarter of 2001. Accordingly, the Company recorded a restructuring charge against operating income in 2000 of \$11.9 million, which included a \$10.4 million write-off of production assets. The total charge included an accrual of \$1.5 million for cash costs to be incurred in 2001, mainly for severance costs and for other shutdown-related costs. In the first quarter of 2001, \$0.3 million of costs were charged against this reserve, principally for severance costs, leaving a reserve balance of \$1.2 million as of the end of the first quarter of 2001.

See Note 8 to Consolidated Financial Statements for information regarding contingencies.

* * *

Forward-looking Statements

This Quarterly Report on Form 10-Q contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These forward-looking statements are only predictions and generally can be identified by use of statements that include phrases such as "believe", "expect", "anticipate", "intend", "plan", "foresee" or other words or phrases of similar import. Similarly, statements that describe the Company's objectives, plans or goals also are forward-looking statements. The Company's operations are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement. The forward-looking statements included herein are made only as of the date of this Quarterly Report on Form 10-Q and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. No assurances can be given that projected results or events will be achieved.

15

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Reference is made to Management's Discussion and Analysis of Financial Condition and Results of Operations in the Form 10-K for a discussion of "Market-Sensitive Instruments and Risk Management." As of December 31, 2000, equity-related financial instruments employed by the Company to reduce market risk included long contracts valued at \$40.1 million. At April 1, 2001, the value of long contracts was \$6.0 million. Such instruments are marked-to-market each month, with unrealized gains and losses included in the results of operations. As such, there is no economic cost to the Company at April 1, 2001 to terminate these instruments and therefore the fair market value is zero.

PART II

OTHER INFORMATION

- Item 6. Exhibits and Reports on Form 8-K
- (a) No Reports on Form 8-K were filed during the quarter ended April 1, 2001.

17

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTERNATIONAL SPECIALTY PRODUCTS INC.

DATE:	May 15, 2001	BY:	/s/Randall R. Lay
			Randall R. Lay
			Executive Vice President and
			Chief Financial Officer
			(Principal Financial and
			Accounting Officer)